Our new combination of antimicrobials to treat viral infections (HY-008B6) is to address the COVID-19 pandemic and is about to start Phase 2 clinical trials.
Our cost efficiencies at every stage of development and post-approval commercialisation permit potential profitability in a field where this is has not been prioritised. Our lead antibiotic programme HY-001B1 (Zidistin®) is initially being developed for complicated urinary tract infections (cUTI). There are 5m cases of UTI in the developed markets each year which corresponds to 35m days of treatment per year. We intend to expand the authorised applications to many more indications such as intraabdominal infections.
Given Zidistin®’s competitive advantages over incumbents we assume the following market shares to model expected profitability:
Year 1: 1%, Year 2: 3%, Year 3: 7%, Year 4: 12%, Year 5: 15%.